Benign Prostatic Hyperplasia (BPH) Treatment Market to Reach $22.15 Billion by 2035

The benign prostatic hyperplasia (BPH) treatment market was valued at $13.09 billion in 2025 and is projected to reach $22.15 billion by 2035, growing at a CAGR of 5.4% during the forecast period (2026–2035). The increasing global population of aging men is a key macro driver, significantly contributing to market expansion. According to the As BPH prevalence rises sharply with age, impacting nearly 50% of men aged 50 and above, this demographic trend is accelerating demand for effective treatment solutions, including medications, minimally invasive therapies (MITs), and surgical procedures. The growing burden of urological disorders is further intensifying the need for early diagnosis and long-term management of BPH. Increasing awareness, improved healthcare access, and the expansion of urology care infrastructure are supporting the adoption of advanced therapeutic approaches. Minimally invasive therapies, such as implant-based and thermal therapies, are gaining strong traction due to reduced recovery time, lower complication risks, and improved patient outcomes. These advancements are positioning MITs as a rapidly expanding segment within the BPH treatment landscape.

Browse the full report description of “Benign Prostatic Hyperplasia (BPH) Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Medications, Minimally Invasive Therapies (MITs), Surgical Procedures), By Drug Class (Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 (PDE5) Inhibitors, Anticholinergics, Beta-3 Agonists), By Procedure Type (Endoscopic Procedures, Laser-Based Procedures, Ablation-Based Procedures, Implant-Based Procedures), By Technology (Thermal Therapy, Laser Technology, Radiofrequency Ablation, Mechanical Implants), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/benign-prostatic-hyperplasia-treatment-market

Rising Aging Population and Urological Disease Burden Driving Market Demand

Globally, healthcare systems are witnessing a surge in BPH-related cases, largely driven by aging demographics and lifestyle-related risk factors. According to the Governments are increasingly prioritizing men’s health programs and urological care initiatives, leading to improved screening rates and treatment adoption.

In response, healthcare providers are expanding access to outpatient and minimally invasive procedures. Technologies such as laser-based therapies and radiofrequency ablation are being increasingly integrated into treatment protocols, improving clinical efficiency and patient satisfaction. These developments are reinforcing the demand for innovative and cost-effective BPH treatment options globally.

Innovation Leaders Transforming the BPH Treatment Market

The key players in the benign prostatic hyperplasia (BPH) treatment market include GlaxoSmithKline, Teleflex Incorporated, Astellas Pharma Inc., Boston Scientific Corporation, and Eli Lilly and Company, among others. These companies are focusing on product innovation, clinical advancements, and geographic expansion to strengthen their market positions.

• In February 2026, Griffin Health announced the availability of Aquablation therapy, a minimally invasive treatment for Benign Prostatic Hyperplasia, a common enlarged prostate condition affecting many older men. The procedure uses ultrasound-guided, robotic-assisted waterjet technology to precisely remove excess prostate tissue while protecting surrounding anatomy, providing faster symptom relief than long-term medications and reducing side effects such as dizziness, low blood pressure, and sexual dysfunction.

• In December 2025,

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  o Treatment Type
  o Drug Class
  o Procedure Type
  o Competitive Landscape – GlaxoSmithKline (GSK), Teleflex Inc. (UroLift), Astellas Pharma Inc., Boston Scientific Corp. (Rez?m), Eli Lilly and Company, among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Benign Prostatic Hyperplasia (BPH) Treatment Market Segment

By Treatment Type

• Medications
• Minimally Invasive Therapies (MITs)
• Surgical Procedures

By Drug Class

• Alpha Blockers
• 5-Alpha Reductase Inhibitors
• Phosphodiesterase-5 (PDE5) Inhibitors
• Anticholinergics (Adjunct use)
• Beta-3 Agonists

By Procedure Type

• Endoscopic Procedures
• Laser-Based Procedures
• Ablation-Based Procedures
• Implant-Based Procedures

By Technology

• Thermal Therapy
• Laser Technology
• Radiofrequency Ablation
• Mechanical Implants

Global Benign Prostatic Hyperplasia (BPH) Treatment Market Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/benign-prostatic-hyperplasia-treatment-market